FS
Fernanda Salles Seguro

Well Cited

103
Works
252
Citations
9
H-Index
Search Authors
Author Statistics
External Links
OpenAlex Profile ORCID Profile

Fernanda Salles Seguro

Also known as: F B Seguro, F S Seguro, F Seguro, F. S. Seguro, F. Seguro

103

Total Works

252

Citations

9

H-Index

9

i10-Index

Citation & Works Trend by Year
20 years active
Top Research Topics
Chronic Lymphocytic Leukemia Research (45) Chronic Myeloid Leukemia Treatments (37) Multiple Myeloma Research and Treatments (36) Myeloproliferative Neoplasms: Diagnosis and Treatment (19) Lymphoma Diagnosis and Treatment (13)
Recent Publications
15 shown
Year Publication Title Citations Action
2026 Real-world treatment patterns, outcomes, and healthcare resource use for myelofibrosis in Brazil: Subgroup analysis of the METER study Hematology Transfusion and Cell Therapy 0
2026 APRESENTAÇÃO ATÍPICA DE LEUCEMIA DE CÉLULAS PLASMOCITÁRIAS COM CARCINOMATOSE PERITONEAL: UM RELATO DE CASO Hematology Transfusion and Cell Therapy 0
2026 IMMATURE AND EXHAUSTED NK/T-CELL PROFILE PRECEDES MOLECULAR RELAPSE AND PREDICTS TREATMENT-FREE REMISSION FAILURE: DATA FROM THE DES-CML TRIAL Hematology Transfusion and Cell Therapy 0
2026 CARACTERÍSTICAS DE POLICITEMIA VERA EXON 12 MUTADO EM UM SERVIÇO TERCIÁRIO DOAJ (DOAJ: Directory of Open Access Journals) 0
2026 Patient-reported Outcomes and Healthcare Provider Perspectives on Subcutaneous Isatuximab Delivery via On-body Injector Versus Manual Injection: Results From the Phase 2 IZALCO Study in Relapsed/Refractory Multiple Myeloma Clinical Lymphoma Myeloma & Leukemia 0
2026 PA-306 MGUS With Advanced Chronic Kidney Disease: Clinical Profile, FLC Ratio Interpretation, and Progression to Multiple Myeloma in a Tertiary Hematology Center Clinical Lymphoma Myeloma & Leukemia 0
2026 PA-166 Efficacy and Safety of Isatuximab Subcutaneous Plus Carfilzomib and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma: Updated Results From the Phase 2 IZALCO Study Clinical Lymphoma Myeloma & Leukemia 0
2026 Updated results from the phase 2 IZALCO study: Efficacy and safety of isatuximab subcutaneous plus carfilzomib and dexamethasone in relapsed/refractory multiple myeloma. Journal of Clinical Oncology 0
2026 Outcomes of dengue infection in adults with underlying haematological diseases in Brazil during 2024 and 2025 British Journal of Haematology 0
2025 Efficacy and safety of isatuximab subcutaneous plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma: results of the Phase 2 study IZALCO Blood Cancer Journal 5
2025 Clinical outcomes of patients with chronic myeloid leukemia with asciminib provided by a compassionate program in Brazil Blood Global Hematology 0
2025 RISK STRATIFICATION IN SMOLDERING MULTIPLE MYELOMA: IMPLICATIONS FOR EARLY INTERVENTION IN RESOURCE-CONSTRAINED SETTINGS Hematology Transfusion and Cell Therapy 0
2025 MUTAÇÃO DRIVER ON DRIVER EM NEOPLASIA MIELOPROLIFERATIVA: UM RELATO DE CASO Hematology Transfusion and Cell Therapy 0
2025 IMMUNE MATURATION AND CHECKPOINT DYNAMICS DURING TYROSINE KINASE INHIBITOR DOSE REDUCTION PREDICT RELAPSE RISK IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA UNDERGOING TREATMENT DISCONTINUATION Hematology Transfusion and Cell Therapy 0
2025 Best Estimated GFR at Follow-Up as a Fundamental Predictor of Overall Survival in Patients with Newly Diagnosed Multiple Myeloma Journal of the American Society of Nephrology 0

Data source: OpenAlex API